A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors - PubMed (original) (raw)

Review

. 2021 Apr 6;33(4):732-739.

doi: 10.1016/j.cmet.2021.02.016. Epub 2021 Mar 9.

Affiliations

Free article

Review

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors

Taha Sen et al. Cell Metab. 2021.

Free article

Abstract

Sodium glucose co-transporter (SGLT) 2 inhibitors reduce the risk of kidney failure in patients with and without type 2 diabetes (T2D). Although the precise underlying mechanisms for these nephroprotective effects are incompletely understood, various hypotheses have been proposed including reductions in intraglomerular pressure through restoration of tubuloglomerular feedback, blood pressure reduction and favorable effects on vascular function, reduction in tubular workload and hypoxia, and metabolic effects resulting in increased autophagy. Here, we review these mechanisms, which may also explain the beneficial effects of SGLT2 inhibitors on kidney function in patients without T2D.

Keywords: chronic kidney disease; nephropathy; sodium glucose co-transporter 2 inhibitors; type 2 diabetes.

Copyright © 2021 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.J.L.H. is supported by a VIDI (917.15.306) grant from the Netherlands Organization for Scientific Research; has served as a consultant for AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bayer, Chinook, CSL Pharma, Gilead, Janssen, NovoNordisk, Merck, Mundipharma, Mitsubishi Tanabe, and Travere; and has received grant support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen.

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources